Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802313 | 0.97 | MAPT (0.48) | MAPTALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL6802311 | 0.97 | MAPT (0.48) | MAPTALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL6803466 | 0.94 | LMNA (0.49) | MAPTALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL6797833 | 0.94 | LMNA (0.49) | MAPTALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL6800704 | 0.93 | NPC1 (0.44) | MAPTALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL6807160 | 0.93 | LMNA (0.49) | MAPTALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL6807163 | 0.93 | LMNA (0.49) | MAPTALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL6802303 | 0.92 | MAPT (0.44) | MAPTALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL6802300 | 0.92 | MAPT (0.44) | MAPTALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL6806416 | 0.91 | MAPT (0.42) | MAPTALDH1A1HPGDLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762321-B2 | SUCH AS N-(2-(3,4-DIMETHOXYPHENYL)ETHYL)-3-DIFLUOROMETHOXY-2-(4 -METHYLPHENYL)ACRYLAMIDE; FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-07-13 | — | — | US | disclosed |
| US-20030195354-A1 | Amide compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1295868-A1 | AMIDE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195354-A1 | Amide compounds and use thereof | CBR1, CBR3, NAT1 | MAPT 3676/4885ALDH1A1 244/4885HPGD 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.